Moderna said its Covid-19 vaccine booster shot produced a “robust” antibody response against the highly contagious delta variant, according to details of a study released Thursday with the company’s second-quarter earnings report.
In a phase-two trial, Moderna is testing a 50-microgram dose of three vaccine booster candidates in previously vaccinated individuals. The booster shots produced a promising immune responses against three variants, including delta, with antibody levels approaching those seen in previously unvaccinated people who received two 100-microgram doses, the company said.
The data has been submitted to a peer-reviewed journal for publication, it said.
The company’s second-quarter financial results also beat Wall Street expectations on earnings and revenue. Here’s how Moderna did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
- EPS: $6.46 per share versus $5.96 per share expected
- Revenue: $4.35 billion versus $4.2 billion expected
Moderna also said a final analysis of its phase three study found the two-dose vaccine was 93% effective, with efficacy “remaining durable” through six months after administration of the second dose.
Moderna, which was founded in 2010, was the second company to gain U.S. authorization for its Covid vaccine behind Pfizer-BioNTech. Moderna’s Covid vaccine generated $4.2 billion in sales in the three months ended June 30, according to the earnings report.
This is a developing story. Please check back for updates.